Solid Biosciences (SLDB) Notes Payables (2024 - 2026)

Solid Biosciences (SLDB) has 3 years of Notes Payables data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables fell 30.21% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (down 30.21% YoY), and the FY2025 full-year result was $9.2 million, up 192.06% from the prior year.
• Notes Payables retreated to $3.4 million in Q1 2026, from $9.2 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $9.2 million in Q4 2025 to a low of $3.2 million in Q4 2024.
• A 3-year average of $5.2 million and a median of $4.8 million in 2025 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 192.06% in 2025 and sank 30.21% in 2026, its largest moves.
• Tracing SLDB's Notes Payables over 3 years: stood at $3.2 million in 2024, then soared by 192.06% to $9.2 million in 2025, then plunged by 63.59% to $3.4 million in 2026.
• Business Quant data shows SLDB's Notes Payables at $3.4 million in Q1 2026, $9.2 million in Q4 2025, and $6.6 million in Q3 2025.